Clinical Trials Sponsored by JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Total 999 results

Janssen Research & Development, LLC

Completed

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women

Healthy

Netherlands, Germany, Belgium
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)

Depressive Disorder, Treatment-Resistant
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Obesity

United States, Belgium, United Kingdom, Sweden, Poland, Canada
Janssen Research & Development, LLC

Completed

A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

Attention Deficit Disorder With Hyperactivity

United States
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Adenocarcinoma of Lung

Spain, Belgium, United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (TEXT-TKR)

VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Belgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
Janssen Research & Development, LLC

Completed

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Attention Deficit Disorder With Hyperactivity

United States
Janssen Research & Development, LLC

Completed

Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

Alzheimer Disease

France, Belgium, Germany, Spain, Sweden
Janssen Research & Development, LLC

Completed

A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom, United States, Belgium, Germany, Romania, Canada, Netherlands, Russian Federation, Poland, Hungary, Czechia
Janssen Research & Development, LLC

Completed

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States
Janssen Research & Development, LLC

Terminated

A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

France, United Kingdom, Spain, Belgium, Netherlands, Germany, Denmark
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

Depressive Disorder, Major

United States, Poland, United Kingdom, Russian Federation, Canada
Janssen Research & Development, LLC

Completed

Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

HIV-1

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Postmenopausal | Metastatic ER+ Her2- Breast Cancer

United States, France, Ukraine, United Kingdom, Belgium, Spain, Netherlands, Korea, Republic of, Russian Federation, Poland, Luxembourg, Ireland
Janssen Research & Development, LLC

Completed

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Fluoroquinolone Associated Disability

Sinusitis | Urinary Tract Infections | Bronchitis

United States
Janssen Research & Development, LLC

Completed

A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, France, Ukraine, Germany, Israel, Poland, Bulgaria, Romania, Russian Federation, Canada, Netherlands, Belgium, Hungary
Janssen Research & Development, LLC

Completed

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

Healthy

Japan, United Kingdom
Janssen Research & Development, LLC

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Multiple Myeloma

United States, Spain, Canada
Janssen Research & Development, LLC

Completed

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States, Australia, France, United Kingdom, Belgium, Germany, Spain, Canada, Netherlands, Greece, Sweden
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

Multicentric Castleman's Disease

United States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Israel, Korea, Republic of, Singapore, Brazil, Belgium, New Zealand, Norway, Egypt, Hong Kong
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir

Renal Insufficiency

United States
Janssen Research & Development, LLC

Completed

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

Multiple Myeloma

United States, Netherlands, Sweden, Denmark
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Multicentric Castleman's Disease

United States, Canada, France, United Kingdom, China, Germany, Taiwan, Spain, Belgium, Israel, India, Korea, Republic of, Netherlands, Singapore, Brazil, Russian Federation, New Zealand, Hungary, Norway, Australia, Egypt, Hong Kong, Malaysi...
Janssen Research & Development, LLC

Completed

A Study of Golimumab in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

Poland, Ukraine, United States, Germany, Belarus, Spain, Romania, Russian Federation, Hungary, Lithuania, Australia, Canada
Janssen Research & Development, LLC

Withdrawn

Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

Germany
Janssen Research & Development, LLC

Withdrawn

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

Healthy

United States
Janssen Research & Development, LLC

Completed

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Prostate Cancer

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Psoriasis

United States
Janssen Research & Development, LLC

Completed

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

Pain | Osteoarthritis

United States, Australia, Poland, Korea, Republic of, Canada, Germany, Hungary, Spain, Czechia, Sweden, United Kingdom
Janssen Research & Development, LLC

Completed

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

Diabetes Mellitus, Type 2

3

Subscribe